Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-3170
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran) ; volume:22 ; number:12 ; day:21 ; month:10 ; year:2020 ; pages:1-7 ; date:12.2020
Current cardiology reports ; 22, Heft 12 (21.10.2020), 1-7, 12.2020
- Creator
-
Sinning, David
Landmesser, Ulf
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11886-020-01427-6
- URN
-
urn:nbn:de:101:1-2020122013352696693118
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sinning, David
- Landmesser, Ulf
- SpringerLink (Online service)
Other Objects (12)
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
Low-density lipoprotein cholesterol lowering treatment: the current approach
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Aggressive low-density lipoprotein (LDL) lowering for primary prevention: still an elusive goal
Leptin decreases the expression of low-density lipoprotein receptor via PCSK9 pathway: linking dyslipidemia with obesity
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
The effect of the heart rate lowering drug Ivabradine on hemodynamics in atherosclerotic mice